Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Amplo Biotechnology Secures Fast Track STTR Funding for AMP-201, a Promising Gene Therapy Targeting Collagen Q Deficiency
Amplo Biotechnology, a leading US-based biotech company dedicated to developing innovative AAV-based gene therapy for […]
Hansa Announces Global Pivotal Phase 3 Trial in Anti-GBM Disease
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, today announced the first […]
Biological Dynamics Case Report Published in "Frontiers in Oncology" Demonstrates Advancement in the Detection of Early-Stage Pancreatic Lesions
Biological Dynamics, a life sciences company focused on developing and commercializing exosome isolation technology for […]
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
Amplia Therapeutics is pleased to announce new data showing the efficacy of its investigational FAK […]
Acurex Biosciences Appoints Esteemed Biopharmaceutical Leader Dr. Robert Booth to its Board of Directors
Acurex Biosciences, a biopharmaceutical company with a mission to stop neurodegeneration before it begins, announces […]
Terran Biosciences Announces New Breakthroughs in the Chemistry of MDMA
Terran Biosciences, a biotech platform company dedicated to the development of transformational therapeutics for neurological […]
Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY® (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder
Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure […]
IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
Positive high-level results from the DUO-E Phase III trial showed IMFINZI® (durvalumab) in combination with […]
Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer
Shattuck Labs, a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a […]
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101
Dyne Therapeutics, a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more